Solomon Seeks $3.8M From Spirogen For AstraZeneca Deal

Law360, New York (May 2, 2014, 8:56 PM EDT) -- Investment banking advisory firm Peter J. Solomon Co. is suing a British biotech company, formerly known as Spirogen Ltd., seeking $3.75 million in fees for advising the company in its $200 million sale to an AstraZeneca PLC subsidiary, according to a complaint filed in New York court Friday.

Solomon Co. alleged it had a contract with Spirogen, which is now operating as a British company called ADC Products Ltd., to provide financial advisory services in connection with a possible sale of the company but never received...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.